Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Evaluating the safety of a new drug to reduce heart disease symptoms
Research Study

Efficacy and Safety of NNC6019-0001 at Two Dose Levels in Participants with Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Principal Investigator
Margot Davis

Overview

Body Locations and Systems
Blood, Heart and Circulation
Disorders and Conditions
Cancers
ClinicalTrials.gov#
NCT05442047
Status
Recruiting
Start/End Dates
Jun 1, 2023 Jun 30, 2025
Locations
Gordon and Leslie Diamond Health Care Centre
Name/Title
Sydney Thorsteinsson, Cardiology Research Coordinator
Phone
604-875-5106
Email Address
sydney.thorsteinsson@vch.ca
Purpose of Study

The purpose of this study is to test a potential new medicine, NNC6019-0001, for people who have heart disease due to transthyretin (TTR) amyloidosis. The study will compare the new medicine at two dose levels (10 mg/kg and 60 mg/kg) to placebo on change in a 6-minute walk test and N-terminal pro-brain natriuretic peptide (NT-proBNP) test from baseline to week 52, or occurrence of death or cardiovascular hospitalization, in participants with hereditary transthyretin amyloidosis or wild-type transthyretin amyloid cardiomyopathy.

Eligibility

Visit ClinicalTrials.gov for more information.

Disclaimer

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.

Share

  • Facebook
  • Linkedin
  • Twitter
  • Email

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy